All Articles

Interim analysis of the part 2 dose-expansion portion of an ongoing 2-part phase 1 Japanese study shows that the FGFR1 tyrosine kinase inhibitor E7090 was active with a manageable safety profile in CCA patients with FGFR2 gene fusion.

Preliminary recommendations made based on cases from the SOLAR-1 trial suggest that alpelisib-induced hyperglycemia can be managed with early detection, close monitoring, and prompt intervention.

For patients with early HR-positive, HER2-positive breast cancer who initiated neratinib within 1 year of completing trastuzumab and in patients who did not achieve a pathologic complete response after neoadjuvant treatment, neratinib may be a cost-effective treatment option.

Participation in certified educational activities resulted in significant improvements in knowledge, competence, and confidence regarding the use of CDK4/6 inhibitor therapies in the management of patients with advanced HR-positive breast cancer.

The combination of exemestane and entinostat did not show survival benefit in patients with aromatase inhibitor–resistant, HR-positive, HER2-negative advanced breast cancer.

Subgroup analysis of the phase 3b CompLEEment-1 clinical trial supports the use of ribociclib combined with letrozole in HR-positive, HER2-negative advanced breast cancer male patients based on demonstrated efficacy and safety.

In a predominantly black, low-income population, women with diabetes and incident localized breast cancer had decreased overall survival when compared with those without diabetes.

Subgroup analysis of the phase 3b CompLEEment-1 clinical trial reinforces the efficacy and safety of ribociclib plus letrozole in premenopausal patients with HR-positive, HER2-negative advanced breast cancer.

An alternative schedule of palbociclib reduced grade ≥3 neutropenia and showed efficacy data comparable with previous reports.

Findings from this study show that based on the adjusted adherence rate of the combination therapy of exemestane and everolimus, a low-rate adherence was observed.